Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 5 | 2018 | 133 | 1.220 |
Why?
|
| Vesicular stomatitis Indiana virus | 4 | 2015 | 13 | 0.760 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2019 | 157 | 0.740 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2021 | 21 | 0.600 |
Why?
|
| Outpatients | 1 | 2018 | 57 | 0.560 |
Why?
|
| Cisplatin | 1 | 2018 | 81 | 0.550 |
Why?
|
| Interferon-beta | 1 | 2015 | 18 | 0.460 |
Why?
|
| Oncolytic Virotherapy | 1 | 2015 | 16 | 0.460 |
Why?
|
| Interferon-alpha | 1 | 2015 | 70 | 0.450 |
Why?
|
| Mucositis | 1 | 2014 | 8 | 0.440 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 10 | 0.430 |
Why?
|
| Smoking | 2 | 2017 | 531 | 0.350 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 599 | 0.310 |
Why?
|
| Piperazines | 2 | 2001 | 52 | 0.210 |
Why?
|
| Leukemia | 2 | 2001 | 37 | 0.210 |
Why?
|
| Pentosyltransferases | 1 | 2003 | 1 | 0.210 |
Why?
|
| Cytosine Deaminase | 1 | 2003 | 1 | 0.210 |
Why?
|
| Pyrimidines | 2 | 2001 | 62 | 0.210 |
Why?
|
| Retrospective Studies | 5 | 2018 | 3701 | 0.190 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2001 | 9 | 0.180 |
Why?
|
| Arsenicals | 1 | 2001 | 13 | 0.170 |
Why?
|
| Oxides | 1 | 2001 | 18 | 0.170 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2001 | 49 | 0.170 |
Why?
|
| Aged | 7 | 2021 | 10538 | 0.170 |
Why?
|
| Middle Aged | 7 | 2021 | 12125 | 0.160 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2019 | 6 | 0.160 |
Why?
|
| Laryngeal Neoplasms | 1 | 2019 | 16 | 0.160 |
Why?
|
| Humans | 13 | 2021 | 32798 | 0.160 |
Why?
|
| Papillomaviridae | 1 | 2019 | 22 | 0.150 |
Why?
|
| Adult | 6 | 2019 | 9560 | 0.150 |
Why?
|
| Patient Selection | 1 | 2021 | 281 | 0.150 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 68 | 0.140 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 726 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2001 | 456 | 0.140 |
Why?
|
| Prognosis | 2 | 2019 | 1544 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 22 | 0.130 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 326 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 54 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 193 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 4032 | 0.120 |
Why?
|
| Survival Rate | 1 | 2018 | 894 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 16 | 0.120 |
Why?
|
| Bilirubin | 1 | 2015 | 25 | 0.120 |
Why?
|
| Oncolytic Viruses | 1 | 2015 | 8 | 0.120 |
Why?
|
| Male | 6 | 2021 | 19641 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 34 | 0.120 |
Why?
|
| Female | 6 | 2021 | 20261 | 0.110 |
Why?
|
| Anthracyclines | 1 | 2015 | 52 | 0.110 |
Why?
|
| Apoptosis | 3 | 2001 | 362 | 0.110 |
Why?
|
| Mutation | 1 | 2017 | 493 | 0.110 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 247 | 0.110 |
Why?
|
| Radiation Tolerance | 1 | 2014 | 24 | 0.110 |
Why?
|
| Quinazolines | 1 | 2014 | 38 | 0.110 |
Why?
|
| Neoplasms | 2 | 2017 | 761 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2014 | 82 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 5 | 2014 | 160 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2284 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 563 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2014 | 218 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 384 | 0.100 |
Why?
|
| Neoplasms, Experimental | 2 | 2003 | 30 | 0.100 |
Why?
|
| Stroke Volume | 1 | 2015 | 370 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2021 | 3438 | 0.090 |
Why?
|
| Young Adult | 1 | 2018 | 2730 | 0.090 |
Why?
|
| Genes, p53 | 2 | 2017 | 23 | 0.080 |
Why?
|
| Genes, ras | 2 | 2017 | 25 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 2 | 2003 | 169 | 0.060 |
Why?
|
| Genetic Vectors | 2 | 2003 | 120 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2001 | 64 | 0.050 |
Why?
|
| Benzamides | 2 | 2001 | 54 | 0.050 |
Why?
|
| Flucytosine | 1 | 2003 | 1 | 0.050 |
Why?
|
| Prodrugs | 1 | 2003 | 16 | 0.050 |
Why?
|
| Virus Replication | 1 | 2003 | 42 | 0.050 |
Why?
|
| Escherichia coli | 1 | 2003 | 83 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2003 | 82 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 104 | 0.050 |
Why?
|
| Mice | 3 | 2003 | 2511 | 0.050 |
Why?
|
| Animals | 4 | 2017 | 7569 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2002 | 18 | 0.050 |
Why?
|
| Macrophage-1 Antigen | 1 | 2001 | 1 | 0.040 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2001 | 3 | 0.040 |
Why?
|
| bcl-X Protein | 1 | 2001 | 5 | 0.040 |
Why?
|
| Genes, myc | 1 | 2001 | 5 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2001 | 32 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2001 | 49 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2001 | 71 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 88 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 98 | 0.040 |
Why?
|
| Proteins | 1 | 2001 | 142 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2001 | 213 | 0.040 |
Why?
|
| Cell Transformation, Viral | 1 | 2019 | 8 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 58 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2014 | 226 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 470 | 0.030 |
Why?
|
| Computational Biology | 1 | 2017 | 94 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 764 | 0.030 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 14 | 0.030 |
Why?
|
| Clone Cells | 1 | 2017 | 35 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 17 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 428 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 135 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 267 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 84 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 98 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 145 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 316 | 0.030 |
Why?
|
| Idarubicin | 1 | 2015 | 7 | 0.030 |
Why?
|
| Daunorubicin | 1 | 2015 | 27 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 99 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2015 | 83 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 69 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 594 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 168 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 23 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2015 | 239 | 0.030 |
Why?
|
| Phenotype | 1 | 2014 | 638 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 754 | 0.020 |
Why?
|
| DNA, Recombinant | 1 | 2002 | 7 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 2002 | 5 | 0.010 |
Why?
|
| Cricetinae | 1 | 2002 | 39 | 0.010 |
Why?
|
| Interferons | 1 | 2002 | 17 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2002 | 22 | 0.010 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2002 | 14 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2002 | 72 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 152 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 247 | 0.010 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2001 | 3 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 352 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2001 | 14 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2001 | 27 | 0.010 |
Why?
|
| eIF-2 Kinase | 1 | 2001 | 6 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2001 | 2 | 0.010 |
Why?
|
| Genes, abl | 1 | 2001 | 3 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2001 | 8 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2001 | 23 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2001 | 40 | 0.010 |
Why?
|
| Ligands | 1 | 2001 | 78 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2001 | 99 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2002 | 486 | 0.010 |
Why?
|
| Melanoma | 1 | 2002 | 165 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2001 | 287 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2002 | 820 | 0.010 |
Why?
|
| Glioblastoma | 1 | 2001 | 157 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 789 | 0.010 |
Why?
|
| Rats | 1 | 2001 | 1606 | 0.010 |
Why?
|